Results 1 to 10 of about 74,782 (138)

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis [PDF]

, 2009
OBJECTIVES:\ud To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.\ud \ud METHODS:\ud Original studies reporting costs of RA or AS were searched systematically.
Ament, A.J.H.A., Boonen, A., Franke, L.C., Laar, M.A.F.J. van de, Severens, J.L.   +4 more
core   +20 more sources

Disease and psychological status in ankylosing spondylitis. [PDF]

, 2006
Objectives. Psychological factors may be important in the assessment and management of ankylosing spondylitis (AS). Our primary objective was to describe associations between disease and psychological status in AS, using AS-specific assessment tools and ...
Goodacre, J. A., Goodacre, L., Grennan, D., Martindale, J., Smith, J., Sutton, Chris J   +5 more
core   +1 more source

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). [PDF]

, 2020
OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive ...
Baraliakos, X., Bertram, C.C., Bosch, F. van den, Carlier, H., COAST-V Study Grp, COAST-W Study Grp, Deodhar, A., Dougados, M., Ermann, J., Gallo, G., Gensler, L.S., Heijde, D. van der, Landewe, R., Li, X.Q., Maksymowych, W.P., Sieper, J., Tomita, T., Walsh, J.A., Wei, J.C.C., Zhao, F.Y.   +19 more
core   +3 more sources

Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]

, 2008
Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Alten, R., Baraliakos, X., Braun, J., Burmester, G., Fritz, C., Krause, A., Listing, J., Schewe, Stefan, Schneider, M., Sieper, J., Sörensen, H., Zeidler, H.   +11 more
core   +1 more source

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis : 48-week results from the EMBARK study [PDF]

, 2015
Objective: To evaluate the efficacy and safety of etanercept (ETN) after 48 weeks in patients with early active non-radiographic axial spondyloarthritis (nr-axSpA).
Bonin, Randi, Braun, Jürgen, Bukowski, Jack F, Citera, Gustavo, Dougados, Maxime, Jones, Heather, Kotak, Sameer, Logeart, Isabelle, Maksymowych, Walter P, Marshall, Lisa, Pedersen, Ron, Sieper, Joachim, Van den Bosch, Filip, van der Heijde, Désirée, Vlahos, Bonnie, Wajdula, Joseph   +15 more
core   +1 more source

Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice [PDF]

, 2009
The SpAs are a group of overlapping, chronic, inflammatory rheumatic diseases including AS, a chronic inflammatory disease primarily affecting the SI joints.
Elewaut, Dirk, Matucci-Cerinic, Marco
core   +1 more source

Scotland Registry for Ankylosing Spondylitis (SIRAS) – Protocol [PDF]

, 2016
Funding SIRAS was funded by unrestricted grants from Pfizer and AbbVie. The project was reviewed by both companies, during the award process, for Scientific merit, to ensure that the design did not compromise patient safety, and to assess the global ...
Dean, Linda E, Gibson, Jane, Hunter, John, Jones, Elizabeth A, Jones, Gareth T, MacDonald, Alan G, Macfarlane, Gary J, Marshall, David, McEntegart, Anne, Munro, Robin, Sturrock, Roger D   +10 more
core   +1 more source

Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force [PDF]

, 2013
Background: Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). Objective: To define the treatment
Baraliakos, Xenofon, Betteridge, Neil, Braun, Jürgen, Burgos-Vargas, Ruben, Collantes-Estevez, Eduardo, de Wit, Martinus, Deodhar, Atul, Dougados, Maxime, Elewaut, Dirk, Emery, Paul, FitzGerald, Oliver, Gossec, Laure, Helliwell, Philip, Jongkees, Merryn, Kavanaugh, Arthur, Kvien, Tore K, Landewé, Robert, Luger, Thomas, Maccarone, Mara, Mease, Philip, Olivieri, Ignazio, Redlich, Kurt, Reveille, John, Ritchlin, Christopher, Rudwaleit, Martin, Schoels, Monika, Sieper, Joachim, Smolen, Josef S, Van den Bosch, Filip, van der Heijde, Désirée, Wei, James Cheng-Chung, Winthrop, Kevin   +31 more
core   +2 more sources

Level of adherence to prescribed exercise in spondyloarthritis and factors affecting this adherence: a systematic review [PDF]

, 2019
Adherence is a primary determinant of the effectiveness of any intervention. Exercise is considered essential in the management of spondyloarthritis (SpA); however, the overall adherence to exercise programmes and factors affecting adherence are unknown.
Coulter, EH, McDonald, DA, McDonald, MT, Paul, L, Siebert, S   +4 more
core   +2 more sources

Physical activity and sedentary behaviour and their associations with clinical measures in axial spondyloarthritis [PDF]

, 2019
Engaging in physical activity (PA) is a key aspect in the management of axial spondyloarthritis (axial SpA), however, its relationship with clinical measures is unknown.
Cameron, Sara, Coulter, Elaine, McDonald, Marie Therese, Paul, Lorna, Siebert, Stefan   +4 more
core   +3 more sources